NMDA receptor modulation by Esculetin: Investigating behavioral, biochemical and neurochemical effects in schizophrenic mice model.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society April 1, 2024 Iqra Khalid, Uzma Saleem, Bashir Ahmad et al. 11 citations
In a mouse model of schizophrenia induced by ketamine, the natural compound esculetin improved behavioral symptoms, reduced oxidative stress and neuroinflammation, and modulated levels of dopamine, serotonin, and glutamate. Esculetin also increased brain-derived neurotrophic factor (BDNF) in the hippocampus, cortex, and striata, counteracting ketamine-induced reductions. Histopathological changes were observed in test groups. These results suggest esculetin may have therapeutic potential for treating schizophrenia.